

**PROGRAM AT A GLANCE**  
as at 13 May 2018

**Note:**

Please check online Conference program on-site in case of last minute changes.  
<http://kenes-exhibitions.com/biomed/program/>  
Time slots highlighted in light blue indicate company presentations.

**TUESDAY, MAY 15, 2018 – HALL A**

09:30-09:50	<b>Welcome by Conference Chairpersons:</b> Ruti Alon, Founder and CEO, Medstrada Ora Dar, PhD, Israel Innovation Authority Nissim Darvish, MD, PhD, Senior Managing Director, OrbiMed
09:50-10:35	<b>Arie S. Belledegrun MD, FACS</b> , Founder, Kite Pharma; Executive Chairman & Co-Founder, Allogene Therapeutics: "Passing the Torch"
10:35-11:20	<b>Francois Maisonrouge</b> , Senior Managing Director, Evercore Partners: "Health Care in 2020: Will we still Pay for Innovation?"
11:20-11:50	<b>Coffee Break</b>
11:50-17:45	<b>Next Generation Oncology Treatments</b>
	<b>Chair: Prof. David Sidransky, MD</b> , Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner
	<b>Immune Oncology</b>
11:50-11:55	<b>Prof. David Sidransky, MD</b> , Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner
11:55-12:35	<b>Prof. Jeffrey A. Sosman, MD</b> , Director, Melanoma Program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
12:35-12:50	<b>Julian Adams</b> , Chairman & CEO, Gamida Cell
12:50-13:05	<b>Yaron Pereg</b> , CEO, Kahr Medical: "KAHR Medical Dual Signaling Proteins (DSP) Platform - the Next Generation of Cancer Immunotherapy"
13:05-13:20	<b>Tehila Ben Moshe</b> , CEO, Biond Biologics: "Biond Biologics - Translating Great Science to Innovative Bio Therapies"
13:20-13:35	<b>Aviv Boim</b> , CEO, Tikcro Technologies: "Immune Oncology - Selective Blocking Antibodies"
13:35-13:50	<b>Irit Carmi-Levy</b> , Drug Development Manager, BiolineRX: "AGI-134: Small Molecule Inducing Hyper-acute, Multi-arm Immune Response Targeting Tumor-specific Neoantigens"
13:50-15:20	<b>Lunch Break</b>
	<b>Oncology</b>
15:20-15:40	<b>Phil L'Huillier, PhD, MBA</b> , Head, European Innovation Hub, MSD: "MSD Immuno-Oncology Overview"
15:40-16:00	<b>Tal Zaks, MD, PhD</b> , Chief Medical Officer Moderna Therapeutics: "Translating mRNA Vaccines and Therapeutics into IO Agents"
16:00-16:15	<b>Dror Harats, MD</b> , CEO Vascular Therapeutics: "MOSPD2: A Novel Target for Antibody-Mediated Killing of Tumor Cells"
16:15-16:30	<b>Roni Mamluk, PhD</b> , CEO, Ayala Pharmaceuticals: "Ayala - A New Clinical Stage Precision Oncology Company"
16:30-16:45	<b>Ori Kalid</b> , Co-Founder & CEO, Pi Therapeutics: "Novel First-in-class Inhibitors of Protein Degradation - an Unfolding Story"
16:45-17:00	<b>Gil Hakim</b> , President, IL Operations, UroGen Pharma: "Transforming Local Therapies in Urology"
17:00-17:45	<b>Roundtable Discussion: Precision Medicine in Oncology</b> Panelists: <b>Prof. Jeffrey A. Sosman, MD</b> , Director, Melanoma program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center of Northwestern University <b>Phil L'Huillier, PhD, MBA</b> , Head, European Innovation Hub, MSD <b>Tal Zaks, MD, PhD</b> , Chief Medical Officer Moderna Therapeutics <b>Roni Mamluk, PhD</b> , CEO, Ayala Pharmaceuticals <b>Dror Harats, MD</b> , CEO Vascular Therapeutic:
17:45-19:45	<b>Gala Event</b>

**TUESDAY, MAY 15, 2018 – HALL B**

<b>11:50-17:15</b>	<b>Fighting Rare Genetic Diseases Using Novel Therapeutic Approaches</b>
	<b>Chair: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx</b>
11:50-12:00	<b>Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx: "Opening Remarks"</b>
12:00-12:15	<b>Julia Hawkins, Partner, LocalGlobe: "The Journey of a Parent to a Child with a Rare Genetic Condition"</b>
12:15-12:35	<b>Tal Zaks, MD, PhD, Chief Medical Officer Moderna Therapeutics: "Moderna mRNA Therapies for Rare Genetic Diseases"</b>
12:35-12:50	<b>BatSheva Kerem, Founder, SpliSense: "Antisense Oligonucleotide Based Treatment for Cystic Fibrosis"</b>
12:50-13:05	<b>Robert Ward, CEO, Eloxx Pharmaceuticals: "About Eloxx Pharmaceuticals"</b>
13:05-13:20	<b>Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx: "From Small Molecules to Gene Therapy and Everything in Between"</b>
13:20-13:35	<b>Prof. Nissim Benvenisty, MD, PhD, New Stem Ltd: "Human Haploid Pluripotent Stem Cells"</b>
13:35-13:50	<b>Aleks Schein, ART BioScience: "mRNA Therapeutics for the Treatment of Rare Diseases"</b>
<b>13:50-15:20</b>	<b>Lunch Break</b>
15:20-15:35	<b>Natalie Yivgi Ohana, PhD, Founder &amp; Chief Scientist, Minovia Therapeutics: "Mitochondria Augmentation Therapy for Rare Mitochondrial Diseases"</b>
15:35-15:50	<b>Or Kakhlon, Department of Neurology, Hadassah Medical Organization, "Using Small Molecules to Treat Glycogen Storage Disorders: New Mechanistic and Translational Insights"</b>
15:50-16:05	<b>Chris Adams, PhD, MBA, Chief Executive Officer, Cydan II Inc: "Rare Disease Company Formation"</b>
16:05-16:20	<b>Daniel Fischer, Founder at Tevard Biosciences: "A Parent on the Race to Find a Therapy for Dravet Syndrome"</b>
16:20-16:35	<b>Tauhid Ali, PhD, Vice President and Head of TAK-celerator, Takeda: "A Rare Disease Unit within Big Pharma"</b>
16:35-17:15	<p>Panel: <b>Rare Diseases – Not a Rare Success. Developing Therapies for Rare Genetic Diseases</b>  Moderator: <b>Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx</b>  Panelists:  <b>Julia Hawkins, Partner, LocalGlobe</b>  <b>Tauhid Ali, PhD, Vice President and Head of TAK-celerator, Takeda</b>  <b>Chris Adams, PhD, MBA, Chief Executive Officer, Cydan II Inc</b>  <b>Daniel Fischer, Founder at Tevard Biosciences</b></p>
<b>17:45-19:45</b>	<b>Gala Event</b>

**TUESDAY, MAY 15, 2018 – HALL C**

<b>11:50-17:45</b>	<b>Novel Clinical Trial Designs and Technologies to Accelerate Drug Development</b>
	<b>Chair: Iris Grossman, PhD, Chief Scientific Officer, Camp4 Therapeutics</b>
11:50-12:00	<b>Iris Grossman, PhD, Chief Scientific Officer, Camp4 Therapeutics: "Introduction"</b>
12:00-12:20	<b>Iris Grossman, PhD, Chief Scientific Officer, Camp4 Therapeutics: "Regulatory Landscape, from Cures Act to INFORMED, Recent Guidances and Future Perspective"</b>
12:20-12:35	<b>Erhan Bilal, PhD, IBM Research, Computational Biology Center: "Sensor-based Assessment of Parkinson's Disease"</b>
12:35-12:50	<b>Marc Funk, COO &amp; President, Lonza Pharma &amp; Biotech: "Novel Tools to Accelerate Early Drug R&amp;D"</b>
12:50-13:05	<b>Daphna Laifenfeld, PhD, Chief Strategy Officer, Ibx Medical Analytics: "Data Driven Repurposing of Existing Drugs"</b>
13:05-13:50	<b>Panel Discussion</b> Panelists: All
<b>13:50-15:20</b>	<b>Lunch Break</b>
15:20-15:35	<b>Dan Vesely, Co-Founder, CliniCrowd, Partner at Sdemagroup: "Patient-driven R&amp;D and the Power of Crowd Source for Therapeutics"</b>
15:35-15:50	<b>Avital Pushett, Business Development, NeuroSense: "Repurposed and Abbreviated ALS Disease Modifying Therapeutic Development"</b>
15:50-16:05	<b>Yoran Bar, Founder &amp; CEO, BeaconCure: "Accelerating Clinical Submissions via Text Analytics AI"</b>
16:05-16:20	<b>Chen Admati, Head of Intel Pharma Analytics Platform, Intel Corporation "From Sensors to Therapeutics via Machine Learning"</b>
16:20-16:35	<b>Nadav Kidron, CEO, OraMed Pharmaceuticals: "Abbreviated Drug Development: Patient-centered Approaches to Innovation"</b>
16:35-16:50	<b>Natalie Gavriellov, PhD, Scientific Lead, Data2Life: "Patient Voice in R&amp;D - Proactive Drug Safety Monitoring"</b>
16:50-17:05	<b>David Harel, Co-Founder &amp; President, CytoReason: "Data-driven Approach to Discover and Develop Immunotherapy Solutions"</b>
17:05-17:20	<b>Ellen Leinfuss, SVP and Chief Commercial Officer, Certara: "Modeling and Simulations Lead Efficient and Effective Drug Development"</b>
17:20-17:35	<b>Nadav Navon, Chief Operating Officer, Intec Pharma: "The Accordion Pill a Unique Oral Delivery Platform to Enhance Pharmacokinetics and Therapeutic Benefit of Challenging Drugs"</b>
17:35-17:45	<b>Iris Grossman, PhD, Chief Scientific Officer, Camp4 Therapeutics: "Closing Remarks"</b>
<b>17:45-19:45</b>	<b>Gala Event</b>

WEDNESDAY, MAY 16, 2018 – HALL A

09:30-09:50	Aharon Aharon, CEO, Israel Innovation Authority
09:50-10:50	<p><b>Corporate Panel: Corporate Investing: Can Strategics Rescue Cash-Starved Start-Ups?</b>  Moderator: <b>David Cassak</b>, Managing Partner, Innovation In Medtech  Panelists:  <b>Michael Martin, PhD</b>, Global Head, Takeda Ventures, Inc.  <b>Zeev Zehavi</b>, Vice President of Venture Investments, Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC)  <b>Gil Bar-Nahum, PhD</b>, Managing Director, Jefferies International, London, UK  <b>Michal Silverberg</b>, Managing Director, Novartis Venture Fund  <b>Simon Gisby</b>, Managing Director, Deloitte Corporate Finance LLC  <b>William Shen</b>, Executive Director, Business Development, Bristol-Myers Squibb</p>
10:50-11:30	<b>Bruce R. Rosengard, MD</b> , Vice President, External Innovation, Medical Devices, Johnson and Johnson Medical Devices : <b>"Innovation: Challenges and Creative Solutions"</b>
11:30-12:00	Coffee Break
12:00-17:15	<b>Nanomedicine and its Role in New Medical Therapeutics</b>
	<b>Chair: Prof. Simon Benita, PhD</b> , Head of Nano Delivery Systems, Hebrew University of Jerusalem
	<b>Session 1: Nanomedicine: Future Promises</b>
12:00-12:30	<b>Anand Subramony, PhD</b> , Vice President, Novel Product Technologies, MedImmune: <b>"Nanomedicine and its Role in New Medical Therapeutics"</b>
12:30-13:00	<b>Prof. Dina Ben-Yehuda, PhD</b> , Dean, Hadassah-Hebrew University Faculty of Medicine <b>"Targeted Nanoparticles for Improved Hematological Cancers"</b>
	<b>Session 2: Presentation of Start-ups</b>
13:00-13:15	<b>Alon Moran, CEO</b> , BioNanoSim Ltd: <b>"Innovative Nano-carriers for Improved Delivery and Drug Performance"</b>
13:15-13:30	<b>Amotz Shemi, PhD, CEO</b> , Silenseed Ltd: <b>"RNA Interference is Progressing Toward Commercialization – the Case of Phase 2 in Pancreatic Cancer"</b>
13:30-13:45	<b>Yoram Ashery, CEO</b> , Nobio Ltd: <b>"Nobio Nanoparticles for Permanent Antimicrobial Protection"</b>
13:45-14:00	<b>Ronen Eavri, PhD, CEO</b> , Barcode Diagnostics: <b>"Barcoded Nanoparticles for Personalized Drug Screening in Cancer Patients"</b>
14:00-15:30	Lunch Break
15:30-15:45	<b>Amir Bahar, PhD, CEO</b> , Nurami Ltd: <b>"Scaffolds of Electrospun Nanofibers for Soft Tissue Repair"</b>
15:45-16:00	<b>Shlomzion Shen, PhD, MBA, CEO</b> , Seevix Material Sciences Ltd: <b>"Seevix Spidersilk "SVXgro": First Man-Made Spidersilk Produced With Bio- and Nano-Technology"</b>
	<b>Session 3: Nanotechnology Up-scaling Challenges: From Bench to the Market</b>
16:00-16:07	<b>Menashe Levy, PhD, CTO</b> , Clexio Biosciences: <b>"Regulatory and CMC Considerations of Nanotechnology Pharma applications"</b>
16:07-16:15	<b>Shimon Amselem, PhD</b> , Chief Scientist, Delivery Technologies, Adama Ltd: <b>"Challenges in the Development and Up-scaling of Liposomes for Diagnostic Imaging"</b>
16:15-16:30	<b>Frederic Lallemand, PhD</b> , Scientist, Santen SAS, <b>"Challenges in the Up-scaling Manufacturing of Cationic Nanoemulsions"</b>
16:30-16:45	<b>Prof. Simon Benita, PhD</b> , Head of Nano Delivery Systems, Hebrew University of Jerusalem: <b>"Challenges in the Development and Up-scaling of Drug-loaded Nanoparticles"</b>
	<b>Session 4 Closing Lecture</b>
16:45-17:15	<b>Prof. Ronit Satchi-Fainaro, PhD</b> , Head, Cancer Angiogenesis & Nanomedicine Laboratory, Sackler Faculty of Medicine, Tel Aviv University: <b>"Reverting Cancer's Poor Prognosis using Precision Nanomedicines Based on Molecular Fingerprints of Long-term vs Short-term Survivors"</b>

WEDNESDAY, MAY 16, 2018 – HALL B

12:00-17:40	<b>From Academic Research to Industry</b>
	<b>Chair:</b> Gil Granot-Mayer, CEO, Yeda R&D – Technology Transfer, Weizmann Institute of Science
	<b>Block 1 – Life Cycle of Technology Transfer – From Initial Disclosure to Success Story</b>
12:00	<b>Gil Granot-Mayer, CEO, Yeda R&amp;D – Technology Transfer, Weizmann Institute of Science; "Introduction"</b>
12:00-12:35	Panel: <b>Looking at Both Sides of the Curtain with Technology Transfer - New Technology Transfer Practices, the Convergence of Digital Technology into the Pharma World, Commercializing Platforms, and Better Understanding of what is Driving TTO Policy</b> Moderator: <b>Mr. Benjamin Soffer, CEO, T<sup>3</sup></b> Panelists: <b>Tamar Raz, CEO, Hadasit; Sylvie Luria, CEO Sheba; Yaron Daniely, CEO, Yisum; Shlomo Nimrodi, CEO, Ramot; Netta Cohen, CEO, BGN Technologies; Gil Granot-Mayer, CEO, Yeda; Larry Loev, CEO, Ariel Scientific Innovations</b>
12:35-13:00	<b>Showcase of New Start-ups from Academia Part 1 of 3</b> Moderator: <b>Larry Loev, CEO, Ariel Scientific Innovations</b> <b>Yitshak Francis, Scientific Advisor, Qrons; Ariel University</b> <b>Yoram Eshel, CEO, On-Sight; Weizmann Institute of Science</b> <b>Prof. Fuad Fares, Founder, CanCuRX; Haifa University</b> <b>Jessica Weiss, CEO, Lydus Medical; Clalit</b>
13:00-13:55	<b>Major Israeli Success Stories in Life Sciences – Fireside Chat with Professors who Championed Academic Innovation into Industry.</b> Moderator: <b>Shay Sela, VP, Business Development of Life Sciences, YEDA</b> <b>Prof. Michel Revel, MD, PhD, Professor Emeritus, Weizmann Institute of Science and Chief Scientist, Kadimastem Ltd</b> <b>Prof. Yechezkel "Chezy" Barenholz, Hebrew University of Jerusalem and Founder of Numerous Startups</b> <b>Prof. Moussa B.H. Youdim, Prof. Emeritus, at the Technion, Founder of Numerous Startups, and President and Chief Scientific Officer at Youdim Pharmaceuticals</b> <b>Prof. Avigdor Scherz, Weizmann Institute of Science and Developed the technology behind Steba BioTech</b>
14:00-15:30	<b>Lunch Break</b>
	<b>Block 2 – Creating the Environment for Successful Technology Transfer:</b>
15:30-16:10	<b>Funding and Performing Translational Research – Models in Taking Bench Side Research to Market. (Collaboration with the IIA; Horizon 2020; NIH; Spark (Stanford) programs)</b> Moderator: <b>Gil Granot-Mayer, CEO, YEDA</b> <b>Michael Salgaller, Supervisor, IDMU, Technology Transfer Center, National Cancer Institute, National Institutes of Health</b> <b>Pasi Sorvisto, Director, SPARK Finland Program</b> <b>Esther Hagai, CEO, FutuRx</b> <b>Prof. Eli Hazum, Head, IDEA program at YEDA</b> <b>Aviv Zeevi Balasiano, VP, Head of Division - Technology Infrastructure Israel Innovation Authority</b> <b>Eyal Zimlichman, Deputy Director General, Chief Medical Officer &amp; Chief Innovation Officer at Sheba Medical Center</b>
16:10-16:30	<b>Showcase of New Start-ups from Academia Part 2 of 3</b> Moderator: <b>Larry Loev, CEO, Ariel Scientific Innovations</b> <b>Nadav Peles, Co-Founder, Acting CEO, Ta Geza; Sheba</b> <b>Noam Shomron, CSO, Variantyx; TAU</b> <b>Tomer Behor, CEO, RenewSenses; Hebrew University</b>
16:30-17:15	<b>View of the Israeli Life Science Ecosystem – How do we Realize the Potential?</b> Moderator: <b>Daphna Murvitz, Co-founder &amp; CEO, 8400 Health Network</b> <b>Zeev Zehavi, Vice President, Venture Investments JnJ; David Sidransky, MD, General Partner at the Israel Biotech Fund</b> <b>Einat Zisman, Former CEO of FutuRx; Yuval Ofek, Founder &amp; Chairman at DayTwo</b> <b>Roni Mamluk, PhD, CEO at Ayala Pharmaceuticals; Itai Kela, Senior Director, Head of Healthcare and Biotechnology, Israel Innovation Authority</b>
17:15-17:40	<b>Showcase of New Start-ups from Academia Part 3 of 3</b> Moderator: <b>Larry Loev, CEO, Ariel Scientific Innovations</b> <b>Daria Lemann-Blumenthal, CEO, Belkin Laser; Sheba</b> <b>Hila Goldman Aslan, CEO, DiA Imaging Analysis; Ben Gurion University</b> <b>Prof. Ayala Pollack, MD, Inventor &amp; Medical Director, OphimedRx; Clalit</b> <b>Seth Salpeter, Co-Founder &amp; CTO, CuResponse, Weizmann Institute of Science</b>
17:40	<b>Gil Granot-Mayer, CEO, YEDA; "Closing Remarks"</b>

WEDNESDAY, MAY 16, 2018 – HALL C

12:00-17:30	<b>Cutting Edge Medical Device Technologies: Metabolic, Ophthalmology</b>
	Metabolic Chairs: <b>Irit Yaniv, MD</b> , General Partner, Accelmed and <b>Prof. Moshe Phillip</b> , Director of the Institute for Endocrinology and Diabetes, Israel National Center for Childhood Diabetes
	Ophthalmology Chair: <b>Barak Azmon, MD</b> , Ophthalmic Entrepreneur
	<b>Metabolic Session (Presentation + Q&amp;A by co-chairs)</b>
12:00-12:17	<b>Yuval Avni</b> , CEO, Beta O2: <b>"Bio Artificial Pancreas"</b>
12:17-12:34	<b>Boaz Behar</b> , CEO, Digma Medical: <b>"Restoring Glycemic Control - Type 2 Diabetes"</b>
12:34-12:51	<b>Eran Atlas</b> , CEO, DreaMed Diabetes: <b>"Ask your Advisor; Decision-Support Technology for Patient-specific Insulin Treatment Plans"</b>
12:51-13:08	<b>Dan Hashimshony, PhD</b> , Medical Device Entrepreneur, CEO, Epitee: <b>"A Self-Administered, Drug-Free Shapeshifting pH Sensitive Super Absorbent Scaffold that Promotes Weight Loss by Balancing Food Consumption"</b>
13:08-13:25	<b>Boaz Brill</b> , CEO, GluSense: <b>"GluSense Glyde™ CGM – a Long-Term Implantable Glucose Sensor"</b>
13:25-13:42	<b>Yael Glassman</b> , CEO, Nutrino Health: <b>"How Personalized Nutrition &amp; FoodPrint™ Contributes to Diabetes Care"</b>
13:42-13:59	<b>Christopher R. Shepard</b> , GM/Chief Executive, SmartZyme BioPharma: <b>"Better Continuous Glucose Monitors with a Next-Generation Glucose-Sensing Enzyme"</b>
14:00-15:30	<b>Lunch Break</b>
	<b>Ophthalmology Session (Presentation + Q&amp;A by co-chairs &amp; panelists)</b> Panelists: <b>Prof. Anat Loewenstein MD, MHA</b> , Head, Ophthalmology Division, Tel Aviv Medical Center <b>Prof. Ehud Assia, MD</b> , Head, Ophthalmology Division, Meir Medical Center <b>Elo Kent</b> , Head, Global Innovation, Santen <b>Barak Azmon, MD</b> , Ophthalmic Entrepreneur
15:30-15:47	<b>Ram Ben-Yehuda</b> , Senior VP Operations, Orcam Technologies: <b>"OrCam - Sophisticated Technology for the Low Vision and Blind"</b>
15:47-16:04	<b>Aryeh Batt</b> , Co-Founder & CEO, Precise Bio: <b>"Bio-manufacturing – Printing the Eye"</b>
16:04-16:21	<b>Nahum Ferera</b> , CEO & Co-Founder, EyeYon Medical: <b>"EyeYon Medical – Innovative Solutions for Corneal Healing"</b>
16:21-16:38	<b>Yaakov Milstain</b> , CEO, Nano-Retina: <b>"Artificial Retina"</b>
16:38-16:55	<b>Shahaf Zommer</b> , Project Manager, BeyeOnics-Elbit <b>"Placing the Surgeon in the Center - A Novel 3D Visualization Platform for Eye Surgery Providing Transparent Display, Data Overlay and Guidance"</b>
16:55-17:12	<b>Marc Abitbol</b> , CEO, Visionix, <b>"Visionix: From the Incubator to a Global Market Leader"</b>
17:12-17:29	<b>Udi Gordon</b> , CEO, CameraEyes: <b>"The Next Generation of Fundus Cameras"</b>

WEDNESDAY, MAY 16, 2018 – HALL D

15:30-17:00	<b>Start-Up Competition</b>
	<b>Alpha Tau Medical</b>
	<b>Neurosteer</b>
	<b>NovaSight</b>
	<b>PixCell Medical</b>
	<b>Brainvivo</b>
	<b>CorNeat Vision</b>
	<b>TemptraMed Israel</b>
	<b>E-Motion Medical Ltd</b>
	<b>Barimote Ltd</b>
	<b>SpacePharma</b>

**THURSDAY, MAY 17, 2018 – HALL A**

09:30-09:45	<b>Winner of Startup Competition</b> Dr. Ami Appelbaum, Chairman IIA
09:45-10:25	<b>Philip Nelson</b> , Director of Engineering at Google Research: <b>"Accelerating Bio Discovery with Machine Learning"</b>
10:25-11:05	<b>Paul R. Biondi</b> , Senior Vice President, Head of Business Development, Bristol-Myers Squibb: <b>"Business Development's Key Role in Delivering the BMS Strategy"</b>
11:05-11:35	Coffee Break
11:35-17:10	<b>Digital Health, IoT, and Big Data - New Armamentarium in Medicine</b>
	<b>Co-Chairs: Anat Naschitz</b> , Managing Director, Orbimed Advisors; <b>Allen Kamer</b> , Managing Partner, OurCrowd Qure
11:35-11:40	<b>Anat Naschitz</b> , Managing Director, Orbimed Advisors
11:40-11:45	<b>Allen Kamer</b> , Managing Partner, OurCrowd Qure
11:45-12:05	<b>Elie Lobel</b> , CEO, Orange Healthcare: <b>"Leveraging Technology &amp; Data For Consumer's Health Improvement"</b>
12:05-12:40	<b>John D. Halamka, MD, MS</b> , Chief Information Officer, Beth Israel Deaconess System: <b>"Emerging Innovations in Healthcare Information Technology"</b>
12:40-13:15	<b>Peter H.J. van der Goes, Jr.</b> , Partner, Head of Healthcare IT and Digital Health Banking at Goldman Sachs: <b>"Healthcare Technology: The Outlook for M&amp;A and Capital Markets Activity"</b>
13:15-13:45	<b>Joshua Milner, MD</b> , Chief, Genetics and Pathogenesis of Allergy Section, National Institute of Health: <b>"Building a System and a Culture of Sharing in the Ever Blurring Line of Clinical and Research Genomics"</b>
13:35-15:05	Lunch Break
	<b>AI AND CYBER</b>
15:05-15:20	<b>Ziv Ofek</b> , Founder and CEO, MDClone: <b>"Liberating the Data: when Big-Data and Innovation Meet"</b>
15:20-15:35	<b>Amir Magner</b> , CEO, CyberMDX: <b>"Strategies for Mitigating Medical Devices Cyber-Security Threats"</b>
	<b>PATIENT DRIVEN CARE</b>
15:35-15:50	<b>Ofer Tzadik</b> , COO, TytoCare: <b>"TytoCare: A New Model for Healthcare Delivery"</b>
15:50-16:05	<b>Ran Shaul</b> , Co-Founder, K Health:
16:05-16:20	<b>Ariel Beery</b> , CEO, MobileODT: <b>"How MobileODT is Disrupting Women's Health using AI/ML"</b>
16:20-16:35	<b>Prof. Amir Lerman, MD</b> , Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic: <b>"Patient Derived Care: The Physician's Perspective"</b>
	<b>DATA AND BIOLOGY – A 2 WAY STREET</b>
16:35-16:50	<b>Prof. Shai Shen Orr</b> , Chief Scientist, CytoReason; Faculty of Medicine, Technion: <b>"CytoReason: A Machine Learning Model of the Immune System for Informed Decision Making in Drug Development"</b>
16:50-17:05	<b>Prof. Zohar Yakhini</b> , School of Computer Science, Herzeliya Inter-Disciplinary Center: <b>"Synthetic DNA – From Regulation to Storage"</b>
	<b>DIGITAL HEALTH COLLABORATES WITH INDUSTRY</b>
17:05-17:25	<b>Philip Nelson</b> , Director of Engineering at Google Research: <b>"Connecting with Industry"</b>

**THURSDAY, MAY 17, 2018 – HALL B**

<b>11:35-17:25</b>	<b>Personalized Diagnostics and Treatments</b>
	<b>Chair: Varda Shalev, MD, MPA</b> , Managing Director, Morris Kahn & Maccabi Research and Innovation Institute at Maccabi Health Care Services
11:35-11:55	<b>Varda Shalev, MD, MPA</b> , Managing Director, Morris Kahn & Maccabi Research and Innovation Institute at Maccabi Health Care Services: <b>“Opening Remarks &amp; Presentation”</b>
11:55-12:20	<b>Miro Venturi, PhD</b> , Global Head - Diagnostics Biomarkers & Personalized Healthcare, F. Hoffmann-La Roche Ltd: <b>“The Future of Personalized Healthcare: The Interplay of Disease, Information and Technologies”</b>
12:20-12:35	<b>Reuven Duer, PhD</b> , Founder & CEO, Proactive Diagnostics: <b>“Monitoring Chronic Inflammation - Proactive Diagnostics”</b>
12:35-13:00	<b>Randy J. Prebula</b> , Partner, Hogan Lovells, Washington, D.C.: <b>“FDA Oversight of Personalized and Precision Diagnostics – Increasing Familiarity and Emerging Flexibility”</b>
13:00-13:15	<b>Ran Shaul</b> , Co-Founder, K Health:
13:15-13:30	<b>Joseph Mossel</b> , CEO & Co-Founder, Ibex Medical Analytics Ltd: <b>“Leveraging AI-based Algorithms and Deep Learning for Prostate Cancer Diagnostics”</b>
<b>13:35-15:05</b>	<b>Lunch Break</b>
15:05-15:30	<b>David Fenstermacher, PhD</b> , VP R&D-Bioinformatics, Medimmune
15:30-15:50	<b>Prof. Gideon Rechavi, MD, PhD</b> , Head, Sheba Cancer Research Center
15:50-16:05	<b>Dekel Taliaz</b> , CEO, Taliaz: <b>“Using AI and Real-world Data for the Design of Decision Support Tools for Doctors”</b>
16:05-16:25	<b>Shai Rosenberg, MD</b> , Neuro-Oncology and Head of Cancer Computational Biology Lab., Hadassah-Hebrew University Medical center
16:25-16:40	<b>David Israeli, MD</b> , CEO, Magenta Medical: <b>“First-in-Man Experience with the Transcatheter Renal Venous Decongestion System for the Treatment of Acute Decompensated Heart Failure”</b>
16:40-16:55	<b>Haim Gil-Ad</b> , CEO, NovellusDx: <b>“NovellusDx - Solving the Missing Piece of Cancer Dx”</b>
16:55-17:10	<b>Lih Segal</b> , CEO, Day Two: <b>“DayTwo Personalized Nutrition Based on Your Gut Microbiome”</b>
17:10-17:25	<b>Eldad Shemesh</b> , Cofounder & CEO, Cardiacsense: <b>“Continuous Monitoring Device for Heart Arrhythmia and Hypertension”</b>



**THURSDAY, MAY 17, 2018 – HALL C**

11:35-17:20	<b>Brain Health</b>
	<b>Chair: Tetsuyuki Maruyama, PhD</b> , Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers
11:35-11:55	<b>Tetsuyuki Maruyama, PhD</b> , Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers: <b>“Where are we in Research, Treatment and Prevention of Alzheimer Disease and Dementia? – Lessons in Drug Development from the Past Year and the Status of the Current Drugs in Late-phase Development”</b>
11:55-13:05	Panel: <b>“Innovations In-development” to Improve Treatment for Brain Diseases - Challenge the Traditional Drug Development Frameworks</b> Moderator: <b>Tetsuyuki Maruyama, PhD</b> , Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers Panelists: <b>Mark Carlton</b> , CSO, Cerevance Therapeutics Norwich Medical School, and the Director of Aging Research in the Norfolk & Suffolk Mental Health Trust <b>Michael C. Irizarry</b> , Vice-President of Early Phase Neurosciences, Eli Lilly <b>Yuval Mor</b> , CEO, Beyond Verbal: <b>“Using Voice and AI to Revolutionize Healthcare by Discovering Vocal Biomarkers”</b>
13:05-13:20	<b>Eyal Baror</b> , CEO, Neuronix Medical
13:20-13:35	<b>Gili Hart</b> , CEO Mitoconix: <b>“Treating Neurodegeneration by Improving Mitochondria Health”</b>
13:35-15:05	<b>Lunch Break</b>
15:05-16:05	Panel: <b>Getting Closer to Validated Biomarkers</b> Moderator: <b>Tetsuyuki Maruyama, PhD</b> , Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers Panelists: <b>Prof. John Gallacher</b> , Director, Dementia Platform UK, University of Oxford <b>Michael C. Irizarry</b> , Vice-President of Early Phase Neurosciences, Eli Lilly <b>Prof. Nir Giladi, MD</b> , Director, Neurology Division, Tel Aviv Sourasky Medical Center
16:05-16:20	<b>Sefi Epel</b> , CEO, BrainMarc: <b>“No Pain No Gain”</b>
16:20-16:35	<b>Adam Shames</b> , Director of Business Development & Strategy, Brainsway: <b>“Deep TMS for the Aging Population”</b>
16:35-16:50	<b>Michal Izrael</b> , VP of R&D ALS & Neurodegenerative Diseases, Kadimastem: <b>“Human Pluripotent Stem Cell Derived Astrocytes for the Treatment of ALS, and Insuling Secreting Islets for the Treatment of Diabetes”</b>
16:50-17:05	<b>Ehab Shakour</b> , CEO, InnoSphere: <b>“InnoSphere Overview”</b>
17:05-17:20	<b>Prof. Jonathan Javitt</b> , Founder & CEO, NeuroRx, Inc: <b>“Suicide is a Druggable Target: Treating Suicidal Depression and PTSD with a Small Molecule NMDA/5-HT2A Dual-targeted Drug Platform”</b>